

					

						November 3, 2017 - By Winifred Garcia
AstraZeneca plc (ADR) (AZN) formed multiple top with $35.47 target or 4.00% above today’s $34.11 share price. AstraZeneca plc (ADR) (AZN) has $85.30 billion valuation. The stock decreased 1.30% or $0.45 during the last trading session, reaching $34.11. About 4,900 shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since November 3, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.Among 4 analysts covering Third Point Reinsurance (NYSE:TPRE), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Third Point Reinsurance had 11 analyst reports since August 7, 2015 according to SRatingsIntel. Wood maintained Third Point Reinsurance Ltd (NYSE:TPRE) rating on Thursday, October 1. Wood has “Market Perform” rating and $15 target. The stock has “Outperform” rating by Keefe Bruyette & Woods on Monday, May 8. The company was maintained on Friday, September 8 by Keefe Bruyette & Woods. The rating was maintained by Keefe Bruyette & Woods on Thursday, August 3 with “Buy”. The stock has “Buy” rating by Keefe Bruyette & Woods on Tuesday, October 10. The firm has “Hold” rating by Keefe Bruyette & Woods given on Monday, October 16. As per Wednesday, September 2, the company rating was maintained by Compass Point. See Third Point Reinsurance Ltd (NYSE:TPRE) latest ratings:16/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold Downgrade10/10/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $16.5 Maintain08/09/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $16.5 Maintain03/08/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $16.5000 Maintain08/05/2017 Broker: Keefe Bruyette & Woods Old Rating: Mkt Perform New Rating: Outperform UpgradeThe stock decreased 0.60% or $0.1 during the last trading session, reaching $16.5. About shares traded. Third Point Reinsurance Ltd (NYSE:TPRE) has risen 10.16% since November 3, 2016 and is uptrending. It has underperformed by 6.54% the S&P500.Investors sentiment increased to 2.46 in 2017 Q2. Its up 1.28, from 1.18 in 2017Q1. It improved, as 9 investors sold Third Point Reinsurance Ltd shares while 19 reduced holdings. 26 funds opened positions while 43 raised stakes. 73.38 million shares or 2.00% more from 71.94 million shares in 2017Q1 were reported. Insight 2811 reported 59,120 shares. Dimensional Fund Advsr Lp, Texas-based fund reported 1.23M shares. State Street owns 0% invested in Third Point Reinsurance Ltd (NYSE:TPRE) for 1.36M shares. 22,888 were reported by Gsa Partners Ltd Liability Partnership. Pnc Financial Svcs Group Inc Inc Inc owns 0% invested in Third Point Reinsurance Ltd (NYSE:TPRE) for 113 shares. Ajo Ltd Partnership stated it has 0.02% in Third Point Reinsurance Ltd (NYSE:TPRE). Massachusetts Ser Communication Ma has invested 0% in Third Point Reinsurance Ltd (NYSE:TPRE). Citigroup holds 0% or 15,304 shares. Swiss Natl Bank holds 0% or 97,000 shares. First Trust Advsr L P invested in 0% or 34,055 shares. Moreover, Wedge Mgmt L Ltd Partnership Nc has 0% invested in Third Point Reinsurance Ltd (NYSE:TPRE). Campbell & Co Adviser Ltd Company invested in 12,178 shares or 0.16% of the stock. Prelude Capital Mngmt Limited Liability invested in 0% or 1,600 shares. Creative Planning holds 0% or 88 shares in its portfolio. Prudential Financial accumulated 52,606 shares or 0% of the stock.Since May 25, 2017, it had 0 insider buys, and 3 sales for $381,750 activity. 5,000 Third Point Reinsurance Ltd (NYSE:TPRE) shares with value of $63,750 were sold by Coleman Christopher S.. $253,000 worth of Third Point Reinsurance Ltd (NYSE:TPRE) was sold by Malloy Daniel V..Third Point Reinsurance Ltd. is a holding company. The company has market cap of $1.77 billion. Through the Company’s reinsurance subsidiaries, it provides property and casualty reinsurance coverage to insurance and reinsurance companies. It has a 8.52 P/E ratio. The Company’s divisions include Property and Casualty Reinsurance, and Corporate.Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. Piperjaffray initiated AstraZeneca plc (ADR) (NYSE:AZN) on Friday, September 23 with “Overweight” rating. Liberum Capital downgraded the shares of AZN in report on Thursday, September 14 to “Hold” rating. Deutsche Bank upgraded the shares of AZN in report on Monday, September 14 to “Buy” rating. HSBC upgraded the stock to “Buy” rating in Wednesday, September 2 report. Credit Suisse downgraded the stock to “Underperform” rating in Tuesday, October 20 report. The stock has “Buy” rating by Bryan Garnier & Cie on Friday, September 18. The rating was maintained by Leerink Swann with “Market Perform” on Monday, October 23. The rating was maintained by Citigroup with “Buy” on Wednesday, October 18. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Buy” rating by BMO Capital Markets on Wednesday, September 6. On Friday, July 31 the stock rating was upgraded by Swedbank to “Buy”.Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on November, 9. They expect $0.50 EPS, down 62.12% or $0.82 from last year’s $1.32 per share. AZN’s profit will be $1.25B for 17.06 P/E if the $0.50 EPS becomes a reality. After $0.87 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -42.53% negative EPS growth. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

		var data = "63557954";
		document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="1262194147"></ins>')
	
(adsbygoogle = window.adsbygoogle || []).push({});